NCT06036927

A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy, safety and pharmacokinetics of TQC2731 injection in the treatment of Chronic Sinusitis with Nasal Polyps.

Conditions

• Chronic Sinusitis
• Nasal Polyps

Interventions

Type	Name	Description
DRUG	TQC2731 injection	TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
DRUG	TQC2731 matching placebo	It'a a placebo injection without active substances.

Timeline

• Start date: 2023-12-08
• Primary completion: 2025-02-05
• Completion: 2025-03-27
• First posted: 2023-09-14
• Last updated: 2025-04-16

Locations

16 sites across 1 country: China